AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen (rintatolimod) in healthy subjects.
Ampligen is an immuno-modulator with broad-spectrum activity being developed by AIM for globally important cancers, viral diseases and disorders of the immune system.
In a statement, the company said data presented in a poster at the British Society for Immunology Congress 2022 showed repeated intranasal administration of Ampligen over the 13-day dosing regimen was well tolerated at all tested dose levels, with no severe or serious adverse events reported.
READ: AIM ImmunoTech says cash position expected to fund operations through end of 2023
At doses evaluated, intranasal Ampligen administration did not drive a significant change in nasal immune cell abundance, the company noted.
AIM CEO Thomas K Equels said the results from this Phase 1 study evaluating intranasal Ampligen in healthy subjects supported the promising potential of Ampligen to inhibit respiratory viruses at the point of entry.
“These Phase 1 data, in combination with the prior promising results of in vitro modelling which demonstrated that Ampligen could decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels, continue to be encouraging as we advance the development of Ampligen as a potential intranasal prophylactic approach to prevent infection and spread of COVID-19,” he said.
The presented poster is available to view on the Events & Presentations page of the company’s website.
AIM is an immuno-pharma company focused on researching and developing therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie